Shopping Cart

Your shopping cart is currently empty

Varespladib

Name: Varespladib
Brand: TargetMol
SKU: T2044
Price: 38 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T2044Cas No. 172732-68-2

Alias LY315920

Varespladib (LY315920), a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.

Varespladib

Copy Product Info

😃Good

Purity: 99.97%

Catalog No. T2044Alias LY315920Cas No. 172732-68-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$38	In Stock	In Stock
5 mg	$89	In Stock	In Stock
10 mg	$147	In Stock	In Stock
25 mg	$239	In Stock	In Stock
50 mg	$355	-	In Stock
100 mg	$513	-	In Stock
200 mg	$743	-	In Stock
1 mL x 10 mM (in DMSO)	$74	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.97%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Varespladib (LY315920), a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.
Targets&IC50	hnsPLA2:7 nM
In vitro	In transgenic mice expressing human sPLA2, oral or intravenous administration of LY315920 (0.3-3 mg/kg) effectively inhibits serum sPLA2 activity in a dose-dependent manner.
In vivo	In the absence of human sPLA2 in BAL cells, LY315920 (0.1 μM-3 μM) effectively suppresses thrombus formation regulated by human sPLA2 in a concentration-dependent manner. Additionally, in a human conjunctival epithelial cell line, LY315920 (10 μM) significantly inhibits the expression of membrane-bound mucin MUC16 induced by all-trans-retinoic acid (RA). LY315920 also markedly inhibits sPLA2 activity across various animal serums, demonstrated by its IC50 values: 8.1 nM in rats, 5.0 nM in rabbits, 3.2 nM in guinea pigs, and 6.2 nM in humans.
Synonyms	LY315920

Chemical Properties

Molecular Weight	380.39
Formula	C₂₁H₂₀N₂O₅
Cas No.	172732-68-2
Smiles	CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1
Relative Density.	1.32 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 60 mg/mL (157.73 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.6289 mL	13.1444 mL	26.2888 mL	131.4440 mL
5 mM	0.5258 mL	2.6289 mL	5.2578 mL	26.2888 mL
10 mM	0.2629 mL	1.3144 mL	2.6289 mL	13.1444 mL
20 mM	0.1314 mL	0.6572 mL	1.3144 mL	6.5722 mL
50 mM	0.0526 mL	0.2629 mL	0.5258 mL	2.6289 mL
100 mM	0.0263 mL	0.1314 mL	0.2629 mL	1.3144 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc